Company / Cash & Equivalents
Lexaria Bioscience Corp. Cash & Equivalents History
FY2015-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$5.8M
FY2022
5-year range
$1.3M / $5.8M
FY2018-FY2022
Trend
+349.3%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents changed +349% YoY in FY2022, a notable deviation from the 6-year average annual change of +138%.
Based on SEC 10-K filings.
$6M in FY2022 with a 5-year CAGR of +86.2%.
Improved from $1M to $6M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +49.9%
- 5-Year CAGR
- +86.2%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +86.2%, indicating consistent growth.
- In FY2022, cash & equivalents increased 349.3% year-over-year.
- Lowest cash & equivalents in the period was in FY2017.
Company context
Key Data Points
- Altman Z-Score -2.77 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | $5.8M | +349.3% |
| FY2021 | $1.3M | +0.7% |
| FY2020 | $1.3M | -25.6% |
| FY2019 | $1.7M | +564.1% |
| FY2017 | $260.1K | +0.0% |
| FY2016 | $260.1K | -63.0% |
| FY2015 | $703.0K | - |
As of FY2022 · SEC 10-K · Updated Jun 24, 2026